2nd line treatment in advanced HCC and when to switch episode artwork

EPISODE · Dec 13, 2024 · 26 MIN

2nd line treatment in advanced HCC and when to switch

from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and  Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch.   The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as:   •          How to approach sequencing in clinical practice •          The available data supporting sequencing strategies •          When to switch to 2nd line therapy and what to consider when doing so   This is the second video podcast episode in a 4-part series. Access the rest of the series here: Part 1 - The use of IO in unresectable HCC Part 3 - Intermediate HCC: treatment options and strategies (coming soon) Part 4 - The evolving role of IO in intermediate HCC (coming soon)   Clinical takeaways   •          Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions •          When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. •          Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered •          Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management •          Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.   Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!   Website: http://www.oncbrothers.com/   X/Twitter: https://twitter.com/oncbrothers   Contact us at [email protected]

Episode metadata supplied by the publisher feed · Published Dec 13, 2024

Embed this episode

NOW PLAYING

2nd line treatment in advanced HCC and when to switch

0:00 26:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Brothers: Practice-Changing Cancer Discussions?

This episode is 26 minutes long.

When was this Oncology Brothers: Practice-Changing Cancer Discussions episode published?

This episode was published on December 13, 2024.

Can I download this Oncology Brothers: Practice-Changing Cancer Discussions episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!